No connection

Search Results

SLN

BEARISH
$7.53 Live
Silence Therapeutics plc · NASDAQ
Target $32.8 (+335.6%)
$2.91 52W Range $7.91
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 20, 2026
Market cap
$355.67M
P/E
N/A
ROE
-90.3%
Profit margin
N/A
Debt/Equity
0.0
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
SLN exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical financial weakness. The company has experienced a catastrophic revenue collapse of -99.90% YoY, rendering traditional valuation metrics like the P/S ratio (636.26) meaningless. While the current ratio of 8.72 suggests a temporary liquidity cushion, the operating margin of -37,150% and negative ROE of -90.27% signal an unsustainable burn rate. The recent price surge is entirely decoupled from financial performance and appears purely speculative.

Key Strengths

High current ratio (8.72) providing short-term liquidity
Zero debt (Debt/Equity 0.00) reducing insolvency risk from leverage
Positive gross margin (61.54%) suggesting potential for product viability
Strong recent short-term price momentum (+139.8% 1Y)
Significant upside gap to analyst target price ($32.80)

Key Risks

Near-total collapse of revenue (-99.90% YoY)
Extreme operational inefficiency (Operating Margin -37,150%)
Critical financial health score (Piotroski 1/9)
Absurd valuation relative to sales (P/S 636.26)
Consistent history of negative earnings and high EPS volatility

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
10
Weak
Value
5
Future
10
Past
20
Health
15
Dividend
0
AI Verdict
Speculative High-Risk
Key drivers: Revenue collapse, Piotroski F-Score 1/9, Extreme P/S ratio, Negative profitability
Confidence
90%
Value
5/100

Ref P/E, PEG, Graham Number

Positives
No standout positives identified.
Watchpoints
  • P/S ratio of 636.26 is extreme
  • No Graham Number available due to lack of earnings
Future
10/100

Ref Growth rates

Positives
  • High analyst target price
Watchpoints
  • Revenue growth -99.90%
  • Q/Q revenue growth -99.86%
Past
20/100

Ref Historical trends

Positives
  • Recent 1Y price recovery
Watchpoints
  • 5Y change of -67.4%
  • Consistent EPS misses
Health
15/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • Zero debt
  • High current ratio
Watchpoints
  • Piotroski F-Score 1/9
  • Negative ROE/ROA
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$7.53
Analyst Target
$32.8
Upside/Downside
+335.6%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for SLN and closest competitors.

Updated 2026-04-17
SLN
Silence Therapeutics plc
Primary
5Y
-67.4%
3Y
+20.9%
1Y
+139.8%
6M
+15.8%
1M
+13.6%
1W
+31.4%
LAB
Standard BioTools Inc.
Peer
5Y
-80.7%
3Y
-51.6%
1Y
-19.1%
6M
-30.5%
1M
-8.2%
1W
-2.2%
PBY
Puma Biotechnology, Inc.
Peer
5Y
-24.3%
3Y
+142.1%
1Y
+151.4%
6M
+33.8%
1M
+17.9%
1W
-7.2%
KRO
Keros Therapeutics, Inc.
Peer
5Y
-80.9%
3Y
-70.2%
1Y
-8.5%
6M
-28.6%
1M
-0.6%
1W
-6.6%
SIG
SIGA Technologies, Inc.
Peer
5Y
+2.3%
3Y
+19.3%
1Y
-0.8%
6M
-35.2%
1M
+10.7%
1W
+9.2%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-10.46
PEG Ratio
N/A
P/B Ratio
5.71
P/S Ratio
636.26
EV/Revenue
1756.82
EV/EBITDA
-12.02
Market Cap
$355.67M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -37150.0%
Gross Margin 61.54%
ROE -90.27%
ROA -30.79%

Growth

Revenue and earnings growth rates

Revenue Growth -99.9%
Earnings Growth N/A
Q/Q Revenue Growth -99.86%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.0
Low debt
Current Ratio
8.72
Strong
Quick Ratio
8.06
Excellent
Cash/Share
$0.6

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
64.7%
Op. Margin
-36650.0%
Net Margin
-34617.6%
Total Assets
$0.1B
Liabilities
$0.1B
Equity
$0.1B
Debt/Equity
1.11x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07
$N/A
2026-03-05
$-0.27
+44.9% surprise
2025-11-06
$-0.15
+27.4% surprise
2025-08-07
$-0.57
-219.3% surprise

Healthcare Sector Comparison

Comparing SLN against 470 companies in the Healthcare sector (26 bullish, 143 neutral, 301 bearish)
Return on Equity (ROE)
-90.27%
This Stock
vs
-97.91%
Sector Avg
-7.8% (Below Avg)
Debt to Equity
0.0
This Stock
vs
3.0
Sector Avg
-99.9% (Less Debt)
Revenue Growth
-99.9%
This Stock
vs
142.9%
Sector Avg
-169.9% (Slower)
Current Ratio
8.72
This Stock
vs
4.65
Sector Avg
+87.4% (Stronger)

Similar Companies

Peer comparison within the same industry

SLN Silence Therapeutics plc
BEARISH
Mkt Cap
$356M
P/E
-
ROE
-90.3%
Price
$7.53
LAB Standard BioTools Inc.
BEARISH
Mkt Cap
$345M
P/E
-
ROE
-13.1%
Price
$0.89
 Compare with SLN
PBYI Puma...
BEARISH
Mkt Cap
$368M
P/E
11.9
ROE
28.0%
Price
$7.24
 Compare with SLN
KROS Keros...
NEUTRAL
Mkt Cap
$341M
P/E
4.9
ROE
19.9%
Price
$11.21
 Compare with SLN
SIGA SIGA Technologies, Inc.
BEARISH
Mkt Cap
$341M
P/E
14.9
ROE
11.2%
Price
$4.76
 Compare with SLN

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-03-05
10-K
10-K
2026-03-05

SLN filed its annual 10-K on March 5, 2026. The provided excerpts identify the locations of the business description, risk factors, and management's discussion and analysis, but contain no specific financial metrics or risk disclosures.

8-K/A
8-K/A
2025-12-22

SLN filed an amendment to a previously submitted Form 8-K on December 22, 2025.

8-K
8-K
2025-12-22
8-K
8-K
2025-12-15
10-Q
10-Q
2025-11-06

SLN filed its 10-Q on November 6, 2025. The provided excerpt identifies the existence of a Risk Factors section, although specific financial highlights and detailed risk disclosures were not included in the available text.

8-K
8-K
2025-11-06
8-K
8-K
2025-10-23

Soluna Holdings, Inc. filed an 8-K on October 23, 2025, likely reporting its third-quarter financial results.

8-K
8-K
2025-08-14

Soluna Holdings, Inc. (SLN) filed an 8-K on August 14, 2025, likely to announce its second-quarter financial results.

10-Q
10-Q
2025-08-07

SLN filed its 10-Q on August 7, 2025. The provided excerpt indicates the inclusion of a Risk Factors section, although specific financial highlights and detailed risk descriptions were not available in the text.

8-K
8-K
2025-08-07
8-K
8-K
2025-06-27
DEF 14A
DEF 14A
2025-05-16
10-Q
10-Q
2025-05-08
8-K
8-K
2025-05-08
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
NONE
5 analysts
HC Wainwright & Co.
2026-03-13
reit
Buy Buy

Past News Coverage

Recent headlines mentioning SLN from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile